The regulator also took issue with how Orexigen Therapeutics presented the risk information
We had SERMO, a social network for physicians, ask about 1,700 physicians what they have to say about the impact of DTC on patient care and choices. Note: It's not pretty.
Pharma marketers are producing plenty of exceptional creative work in the DTC realm. There are also plenty that prompt quick checks to make sure that one hasn't inadvertently clicked over to The Onion.
Mary Skoyles finds that DTC ads are getting better. "There's a lot of interesting work being done," she says. "There are more chances being taken."
Drugmakers again spent more on DTC advertising in 2016 than the year before.
Pfizer and Bristol-Myers Squibb were the top spenders last year.
Pfizer receives subpoena over patient assistance programs; drugmakers raise prices less this January than last; lawmakers have new plan to repeal ACA
Ads promoting Merck's and Bristol-Myers Squibb's immunotherapies could signal the beginning of a new era for DTC.
Allergan said it would increase its investment in DTC after reporting slowing sales for its double-chin injection.
If Trump decides to go after pharma, politicians aren't likely to receive too many "How can you do this? Think about the children!" notes.
The FDA responded to criticism from industry about its proposed research of DTC animation.
Ad pushes behind brands like Gilead Sciences' hepatitis-C pill Harvoni and Allergan's IBS drug Viberzi buoyed med-surg outlays for the first six months of 2016. Cancer drugs once again were the hottest category.
The inside story on a campaign for the ages, as told by the individuals who worked on it.
Given its modern-day ubiquity, it's easy to forget that pharma DTC didn't exist until the 1980s rolled around.
Five decades ago, pharmaceuticals were the protected province of health professionals. Today we have DTC ads, the internet, and pharmacy handouts.
Patients who ask for a prescription after seeing an ad are more likely to get one; Mylan's executive pay is now under scrutiny
Some drugmakers employ unsettling ads; Teva said the FDA may grant quick review for generic EpiPen; Sanofi and Google's Verily partner in diabetes
Shire hires Jennifer Aniston for a disease awareness campaign; critics argue that the direct-to-consumer ads for Opdivo are misleading, while Merck's Keytruda takes the lead in first-line cancer
Critics say the direct-to-consumer ad for the immuno-oncology therapy is misleading.
A new bill exempting CME reporting gains physician support; NYT op-ed calls Opdivo DTC ad "misleading;" Valeant to sell non-core assets worth $8 billion
Physicians debate DTC tax write-off; Novo Nordisk's Victoza shows 13% benefit in reducing cardiovascular risks; Shire to acquire Pfizer bowel drug
Pharma companies took issue with the methodology for the FDA's proposed studies of advertising tactics.
Pfizer buys Anacor; Harvard Medical School loosens rules for faculty ties to pharma; Vermont poised to pass price transparency bill
Advertising lobbyist said eliminating the DTC ad tax deduction is a real threat to the industry.
The loss of patent exclusivity for cancer drug Gleevec contributed to a 12% sales drop, but the drugmaker expects sales from Entresto and Cosentyx to pick up the slack.
Following print's best year since 2011, it's time to rewrite those journal-advertising obituaries. Medical-surgical print journal spending in 2015 was up 8.4% to $372 million.
The launch this week of the first DTC campaign for Viberzi follows a wave of direct-to-consumer campaigns focused on promoting treatments for the two types of IBS.
After buying back the rights to the therapy, the biopharmaceutical company is building a endocrinology sales force and hiring a new advertising agency.
One side effect (pun super-deliberately intended) of prompting pharma creatives to come up with new go-to visuals is that, well, not every idea or execution is a keeper.
DTC is facing a new test from physicians and politicians. Here's why critics fear a deluge, and how they're pushing back.
- Study: One-third of docs trust pharma content on HCP sites
- Five things for pharma marketers to know: Monday, May 22, 2017
- Five things for pharma marketers to know: Tuesday, May 23, 2017
- Five things for pharma marketers to know: Friday, May 19, 2017
- Five things for pharma marketers to know: Wednesday, May 24, 2017
Live at MM&M Transforming Healthcare
In his keynote address at the MM&M Transforming Healthcare conference, Dr. Gautam Gulati says the industry is being outpaced by its innovation.
One executive referred to AI as a "black box" and as the "Tower of Babel."
Execs stressed the importance of collaboration, consumer-mindedness.
The artificial pancreas can provide value to the health system.
MM&M honors 40 upstarts and veteran innovation gurus.
For the first time MM&M honors a group of 10 agency execs.